347 related articles for article (PubMed ID: 32506394)
1. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
2. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in neuroendocrine tumors of the lung.
Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
[TBL] [Abstract][Full Text] [Related]
4. Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
Yoshimura A; Yamada T; Miyagawa-Hayashino A; Sonobe Y; Imabayashi T; Yamada T; Okada S; Shimamoto T; Chihara Y; Iwasaku M; Kaneko Y; Uchino J; Inoue M; Konishi E; Takayama K
Lung Cancer; 2019 Nov; 137():108-112. PubMed ID: 31568887
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
6. A study on expression of programmed death ligand-1 in small cell lung carcinoma and correlation with clinicopathological parameters.
Sudha S; Shukla S; Husain N; Kumar H; Pandey RK; Kant S
Pol J Pathol; 2024; 75(1):25-35. PubMed ID: 38808606
[TBL] [Abstract][Full Text] [Related]
7. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
[TBL] [Abstract][Full Text] [Related]
8. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in large cell neuroendocrine carcinoma of the lung.
Eichhorn F; Harms A; Warth A; Muley T; Winter H; Eichhorn ME
Lung Cancer; 2018 Apr; 118():76-82. PubMed ID: 29572007
[TBL] [Abstract][Full Text] [Related]
11. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
Takada K; Toyokawa G; Okamoto T; Akamine T; Takamori S; Katsura M; Fujishita T; Shoji F; Oda Y; Maehara Y
Anticancer Res; 2016 Jul; 36(7):3409-12. PubMed ID: 27354600
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
16. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Chang YL; Yang CY; Huang YL; Wu CT; Yang PC
Oncotarget; 2017 Mar; 8(11):18021-18030. PubMed ID: 28152514
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
[TBL] [Abstract][Full Text] [Related]
18. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
Xu H; Dong X; Zhao H; Hou T; Chen C; Chen G; Ye J; Li Y
J Clin Lab Anal; 2021 Mar; 35(3):e23696. PubMed ID: 33434308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]